Revolution Medicines Inc

Price Chart

Risk-Adjusted Performance

Revolution Medicines Inc (RVMD) Price Performance

Revolution Medicines Inc (RVMD) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $95.78, down 2.37% from the previous close.

Over the past year, RVMD has traded between a low of $31.13 and a high of $123.27. The stock has gained 149.1% over this period. It is currently 22.3% below its 52-week high.

Revolution Medicines Inc has a market capitalization of $19.15B.

About Revolution Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.